Trunome entered Shark Tank India Season 2 with a genomics-based diagnosis and monitoring platform for chronic diseases. The founders asked for ₹1.5 crore for 1% equity, establishing the starting point for the televised valuation and investment discussion.
The televised negotiation ended with ₹1.5 crore for 2% equity. Those were the announced programme terms; television agreements can remain subject to due diligence and definitive documents, and no later cap table was reviewed for this report.
As of August 27, 2026, the latest traceable position comes from the company’s public-facing material and the cited programme record. Trunome is now presented by Acrannolife Genomics as a non-invasive blood-testing platform for monitoring chronic disease and post-transplant patients. India’s Technology Development Board also announced support for Acrannolife’s indigenous manufacturing of advanced in-vitro diagnostic products. These sources establish continued technical and commercial development, but they do not disclose current audited revenue or valuation.
The before-and-after comparison is between the focused proposition presented in the Tank and the most recent verifiable public footprint. At the pitch stage, the founders were seeking capital, strategic support and national visibility. The latest sources show whether the product, distribution or service remains publicly available and identify any disclosed scale milestone.
Website availability, app-store distribution, product counts and company announcements can demonstrate continued commercial activity. They do not automatically prove sustained customer use, cash collection, profit or enterprise value. For that reason, promotional statements are attributed to the company and are not converted into independent financial conclusions.
No recent audited revenue, profit, headcount or current valuation was located in the public sources reviewed unless expressly stated above. The Shark Tank terms are reported as televised terms and should not automatically be interpreted as confirmation that funds were transferred after due diligence.
The supportable conclusion is measured: Trunome began its Shark Tank journey with a genomics-based diagnosis and monitoring platform for chronic diseases, sought ₹1.5 crore for 1% equity, and left the televised discussion with ₹1.5 crore for 2% equity. Its present position is described only through traceable material, without filling disclosure gaps with estimates.
Sources: Trunome current primary source; Shark Tank India Season 2 pitch record.